Sakar Healthcare Q1 FY26: Small-Cap Pharma or Side Hustle for Oncology Avengers?

1. At a Glance

Sakar Healthcare is that underdog pharmaceutical company you ignored at ₹90 and now it’s yelling “I told you so” at ₹365. Riding high on EU approvals, oncology patents, and export tie-ups, this mini-capsule maker just punched its way into serious markets. But is it still medicine or now just meme stock?

2. Introduction with Hook

Imagine your neighborhood chemist suddenly getting invited to Davos. That’s Sakar.

This Ahmedabad-based company:

• Got two EU marketing authorizations in 2025
• Signed deals across Europe, South America, and the Nordics
• Claimed 292 registered products with 210 more on the way

Yet the ROE is a sleepy 6.4% and promoter holding is melting faster than paracetamol in hot water.

3. Business Model (WTF Do They Even Do?)

Basically, Sakar makes pharmaceuticals—but not your basic Crocin and Hajmola.

We’re talking:

• Oncology drugs (cancer treatments)
• Export-focused R&D (aka paperwork Olympics)
• Contract manufacturing for big boys like Dr. Reddy’s and Biocon
• Now entering regulated EU markets after receiving EU GMP approval

Think of them as the backstage crew that suddenly decided to grab the mic.

4. Financials Overview

• Operating Margin: 24.1%—healthy, unlike their customers.
• Net